Genesee Capital Advisors’s Merck MRK Stock Holding History

Genesee Capital Advisors’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,929	Closed	-$982K	–	128
2024 Q2	$982K	Buy	7,929 +36	+0.5%	+$4.64K	0.48%	45
2024 Q1	$1.04M	Sell	7,893 -75	-0.9%	-$9.24K	0.57%	42
2023 Q4	$869K	Buy	7,968 +765	+11%	+$79.4K	0.54%	44
2023 Q3	$742K	Sell	7,203 -204	-3%	-$22K	0.53%	49
2023 Q2	$855K	Buy	+7,407	New	+$841K	0.58%	47

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Genesee Capital Advisors's MRK Position: Q3 2024 in Review

Genesee Capital Advisors sold out of Merck (MRK) in Q3 2024, closing a stake of 7,929 shares — an estimated $982K sold.

Genesee Capital Advisors first reported a position in MRK in Q2 2023 and held it in 5 quarters. The position peaked at $1.04M in Q1 2024. 3,490 funds tracked by Wall St. Rank hold MRK as of Q3 2024.

Genesee Capital Advisors reported no remaining Merck position as of Q3 2024 after selling out during the quarter.
Genesee Capital Advisors sold 7,929 Merck shares in Q3 2024, an estimated $982K.
Genesee Capital Advisors first reported a position in Merck in Q2 2023 and held it in 5 quarters.
Genesee Capital Advisors's Merck position peaked at $1.04M in Q1 2024.
3,490 funds tracked by Wall St. Rank held Merck as of Q3 2024.

Based on Genesee Capital Advisors's 13F filing for Q3 2024, filed 21 Oct 2024.